iTeos Therapeutics, Inc.
ITOSNASDAQHealthcare
$10.15
+$0.02(+0.20%)
Market Cap$448684810
P/E Ratio—
52W High$17.63
52W Low$4.8
iTeos Therapeutics, Inc. (ITOS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ITOS · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2025Report Date: Aug 6, 2025EPS Actual
-$1.51
Est. -$1.12 · -34.8%
Revenue
—
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Aug 6, 2025
After Market Close
▼ Miss EPS
ITOS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q3 FY2025 | Aug 6, 2025 | -$1.12 | -$1.51 | -34.8% | — | — | — |
| ▲ Q2 FY2025 | Apr 28, 2025 | -$0.94 | -$0.80 | +14.9% | — | $0.00B | — |
| ▲ Q1 FY2025 | Mar 5, 2025 | -$1.14 | -$1.01 | +11.4% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$1.18 | -$1.05 | +11.0% | — | — | — |
| ▲ Q3 FY2024 | Aug 8, 2024 | -$1.04 | -$0.18 | +82.7% | $0.04B | $0.00B | +3400.0% |
| ▼ Q2 FY2024 | May 10, 2024 | -$1.02 | -$1.07 | -4.9% | — | — | — |
| ▲ Q1 FY2024 | Mar 6, 2024 | -$1.03 | -$0.85 | +17.5% | $0.01B | $0.01B | -9.3% |
| ▲ Q4 FY2023 | Nov 7, 2023 | -$1.20 | -$0.90 | +25.0% | — | $0.03B | — |
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$1.51
EPS Est.
-$1.12
EPS Surpr.
-34.8%
Revenue
—
Q2 FY2025
Apr 28, 2025Beat
EPS Actual
-$0.80
EPS Est.
-$0.94
EPS Surpr.
+14.9%
Revenue
—
Q1 FY2025
Mar 5, 2025Beat
EPS Actual
-$1.01
EPS Est.
-$1.14
EPS Surpr.
+11.4%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$1.05
EPS Est.
-$1.18
EPS Surpr.
+11.0%
Revenue
—
Q3 FY2024
Aug 8, 2024Beat
EPS Actual
-$0.18
EPS Est.
-$1.04
EPS Surpr.
+82.7%
Revenue
$0.04B
Q2 FY2024
May 10, 2024Miss
EPS Actual
-$1.07
EPS Est.
-$1.02
EPS Surpr.
-4.9%
Revenue
—
Q1 FY2024
Mar 6, 2024Beat
EPS Actual
-$0.85
EPS Est.
-$1.03
EPS Surpr.
+17.5%
Revenue
$0.01B
Q4 FY2023
Nov 7, 2023Beat
EPS Actual
-$0.90
EPS Est.
-$1.20
EPS Surpr.
+25.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q3 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q2 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q1 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q4 FY2026 | $-0.47 | $-0.47 | $-0.47 | 1 |
| Q3 FY2026 | $-0.55 | $-0.55 | $-0.55 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q3 FY2025 | Aug 6, 2025 | -34.8% | $10.11 | $10.11 | +0.00% |
| ▲ Q2 FY2025 | Apr 28, 2025 | +14.9% | $7.35 | $7.07 | -3.81% |
| ▲ Q1 FY2025 | Mar 5, 2025 | +11.4% | $6.85 | $7.26 | +5.99% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +11.0% | $9.38 | $9.19 | -2.03% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +82.7% | $15.22 | $14.98 | -1.58% |
| ▼ Q2 FY2024 | May 10, 2024 | -4.9% | $12.19 | $17.44 | +43.07% |
| ▲ Q1 FY2024 | Mar 6, 2024 | +17.5% | $11.02 | $11.88 | +7.80% |
| ▲ Q4 FY2023 | Nov 7, 2023 | +25.0% | $10.21 | $10.65 | +4.31% |
Q3 FY2025+0.00%
Report Date
Aug 6, 2025
EPS Beat/Miss
-34.8%
Price Before
$10.11
Price After
$10.11
Q2 FY2025-3.81%
Report Date
Apr 28, 2025
EPS Beat/Miss
+14.9%
Price Before
$7.35
Price After
$7.07
Q1 FY2025+5.99%
Report Date
Mar 5, 2025
EPS Beat/Miss
+11.4%
Price Before
$6.85
Price After
$7.26
Q4 FY2024-2.03%
Report Date
Nov 12, 2024
EPS Beat/Miss
+11.0%
Price Before
$9.38
Price After
$9.19
Q3 FY2024-1.58%
Report Date
Aug 8, 2024
EPS Beat/Miss
+82.7%
Price Before
$15.22
Price After
$14.98
Q2 FY2024+43.07%
Report Date
May 10, 2024
EPS Beat/Miss
-4.9%
Price Before
$12.19
Price After
$17.44
Q1 FY2024+7.80%
Report Date
Mar 6, 2024
EPS Beat/Miss
+17.5%
Price Before
$11.02
Price After
$11.88
Q4 FY2023+4.31%
Report Date
Nov 7, 2023
EPS Beat/Miss
+25.0%
Price Before
$10.21
Price After
$10.65
Avg Beat Reaction+1.78%
Avg Miss Reaction+21.54%
Beat Rate6 / 8 quarters
Largest Move+43.07% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ITOS ends December
iTeos Therapeutics, Inc. (ITOS) most recently reported earnings on August 6, 2025 for Q3 FY2025, posting EPS of $-1.51 — missing the analyst consensus of $-1.12 by -34.8%. The next ITOS earnings date is expected around September 1, 2026.
Each quarter, investors track ITOS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ITOS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ITOS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ITOS earnings · 5 questionsiTeos Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ITOS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ITOS historically reports after market close (AMC).
ITOS earnings datewhen is ITOS earningsITOS next earnings datewhen does ITOS report earningsITOS earnings calendar
▸ Source: FMP · iTeos Therapeutics, Inc. SEC filings · US GAAP · iTeos Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026